Business Wire

SES

27.2.2020 08:52:08 CET | Business Wire | Press release

Share
Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation

Orange, one of the world’s leading multi-service telecommunications operators and present in 18 countries in Africa, will be the first telco to adopt the ground-breaking O3b mPOWER , SES’s next-generation Medium Earth Orbit (MEO) satellite communications system, to exponentially ramp up its consumer and business services, starting in the Central African Republic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226006105/en/

O3b mPOWER is the world’s only fully-funded non-geostationary orbit (NGSO) broadband system in development today. Positioned at only 8,000 kilometres away from Earth, the system will power low-latency high-throughput solutions that can be seamlessly integrated into existing terrestrial networks. When operational in 2022, O3b mPOWER will provide multiple terabits of throughput globally to drive digital transformation and cloud adoption virtually anywhere on the planet.

The highly flexible O3b mPOWER constellation comprises ultra-high-capacity, low-latency, high-power MEO satellites, each with up to 5,000 fully-shapeable and steerable beams that can be shifted and scaled in real-time to meet customers’ demands. The system is ideally suited for domestic cellular backhaul and simultaneous international IP trunking applications.

Orange has been a customer and early adopter of SES’s current generation O3b MEO managed services since 2017. Orange is a strategic partner for SES with its large presence in Africa and the Middle East, and with satellite gateways in several countries on the continent. With O3b mPOWER, Orange will substantially increase its low-latency MEO-enabled capabilities to support the growth of its bandwidth demand, driven by the ever-growing customer base, the new digital uses and financial services. The revolutionary system will enable Orange to offer high broadband and seamless connectivity, while extending geographical reach.

In addition, Orange Central African Republic will leverage the world’s only multi-orbit network, utilising SES’s MEO and GEO (Geostationary Earth Orbit) satellites to connect and aggregate 2G/3G traffic from remote base stations around the country to the core network in the capital of Bangui. This gives the operator a single source for cellular backhaul and core IP transit, as well as a consistent and seamless experience between the MEO and GEO services.

“We are thrilled to be partners and early adopters of this innovation with SES, and to be able to offer high-quality connectivity in the most remote locations of the Central African Republic. This longstanding partnership fully aligns with our mission of building smarter and open networks to bridge the digital divide in Africa, and to increase the speed and geographic reach of our network,” said Jean-Luc Vuillemin, Executive Vice President at Orange International Networks Infrastructures and Services.

“This new agreement marks a very important milestone for both our companies and also for the broader industry. With the innovative O3b mPOWER system, Orange and SES are revolutionising the telco market, and the way networks can be extended and improved,” said JP Hemingway, CEO of SES Networks. “With its ability to power a wide range of telecommunications needs, including cellular backhaul and high-performance cloud connectivity, O3b mPOWER – together with other terrestrial infrastructure – is key to connecting remote and underserved regions in the most economically viable way.”

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of over 355 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye